 |
Lucie EllisExecutive Editor |
Lucie has been covering the ups and downs of the pharmaceutical industry since joining the Informa Pharma Intelligence team in 2012. Prior to being Executive Editor of In Vivo, Lucie was a Senior Editor at Scrip and Pink Sheet. She is responsible for overall content planning and production for In Vivo, and also contributes feature-length articles to the publication on the topics of leadership, R&D, deal trends, innovation and more. |
 |
Ben ComerPharma Editor |
Ben is Pharma Editor at In Vivo, responsible for biopharma industry coverage. His areas of focus include commercialization and R&D strategy, regulation, policy and social issues impacting the sector. Prior to joining In Vivo, Ben was a Senior Manager at PwC’s Health Research Institute and a Senior Editor at Pharmaceutical Executive magazine. |
 |
Ashley YeoMedtech Editor
|
Ashley Yeo delivers content that gives insight into current and future trends in the global medtech industry, and what players need to do, and with whom, to keep ahead of the game in this fast-evolving and highly competitive sector. He currently writes for In Vivo and Medtech Insight as an Executive Editor. Ashley has been with Informa and legacy publications, reporting on all forms of healthcare (plant, animal, human) for over 30 years, having joined as a linguist on the European desk and later becoming editor of three diverse publications. He has also contributed aesthetic medicine and pharma content when a member of the multifunctional team of pharma analysts. His current focus is the strategic rationale of the big players in medtech, on In Vivo; and UK, European and OUS global regulation and policy input on Medtech Insight.. |
 |
Deanna KamienskiSenior Deals Analyst, Biomedtracker |
Deanna has been tracking deal-making activity in the biopharma and medtech industries since 2000. She is currently a Senior Deals Analyst for Biomedtracker and had previously contributed to the Strategic Transactions deals database. Deanna authors a Quarterly Statistics article and other monthly trend pieces for In Vivo. She holds a Bachelor of Science degree from the University of Vermont.
|
 |
Maureen RiordanSenior Deals Analyst, Biomedtracker
|
Currently a Senior Deals Analyst with Biomedtracker and previously a contributor to the Strategic Transactions deals database, Maureen has been reporting on deal-making activity and trends since 1996. She also authors a quarterly deal-making statistics article and other monthly trend pieces for In Vivo. Maureen holds a Bachelor of Arts degree in English from Niagara University, and a Master of Library Science degree from Southern Connecticut State University.
|
 |
Karen ColemanHead of Editorial Ops |
Karen is the Head of Editorial Operations for In Vivo, Pink Sheet, Scrip and Generics Bulletin working with a global team of expert, experienced and respected journalists. She qualified as a pharmacist in South Africa in 2000 where she worked in retail and hospital settings before relocating to the UK in 2002. Karen spent nine months working for the NHS in a variety of hospital pharmacy settings, including Moorfields Eye Hospital. In December 2002 she joined IMS Health (now IQVIA), analyzing patent expiries and generic drug launches in 26 major and emerging markets. Karen joined Informa in 2009, leading a team of analysts publishing Strategic reports covering numerous aspects of the Pharma and Medtech industries. She has held a number of management and leadership roles over the years, ensuring the successful delivery of product enhancements and consolidation, and process improvements, working closely with Editorial, Technical and Commercial teams. |
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.